1 results
Use and experience with six-monthly paliperidone in the Campo de Gibraltar area. Descriptive study.
- C. M. Gil Sánchez, J. A. Salomón Martínez, E. Corbacho Navarro
-
- Journal:
- European Psychiatry / Volume 66 / Issue S1 / March 2023
- Published online by Cambridge University Press:
- 19 July 2023, pp. S1005-S1006
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Introduction
Long-acting injectable antipsychotics have demonstrated advantages over therapeutic adherence and can reduce the rates of relapses and due to treatment discontinuation. The novel presentation of paliperidone palmitate six-month (PP6M) can simplify the treatment to two injections per year.
ObjectivesThe purpose of the present research is to describe the profile of patients receiving this novel treatment in our area. For this, a descriptive study has been carried out.
MethodsWe have collected and analyzed data from a total of 8 patients from the global long-acting injectable nursing registry in our area. The data collection was from May 2022 to October 2022.
ResultsID Patient Age Gender Medical comorbidities Social support Adherence to previous LAI EP001AGC 52 M No - Yes EP002EGA 53 M No Low No EP003ESL 45 F Yes HIV, HCV, dyslipidemia, Enough Yes EP004ACG 60 M Yes Hypertension, dyslipidemia Good Yes EP005DCP 52 M Yes COPD Enough Yes EP006ATT 47 M No Enough / Low Yes EP007AH 40 F Yes Tension headache Enough Yes EP008IAR 66 F Yes Type 2 diabetes mellitus, hypertension, hyperuricemia Enough Yes ID Patient Diagnosis Refractory positive symptoms Last H. Polypharmacy Previous injection Injection date / Dose H. / Side Effects EP001AGC Paranoid schizophrenia - 08/03/2014 No PP3M 525mg 17/05/22 1.000 mg No EP002EGA Schizoaffective disorder Yes 19/08/2022 Yes Valproic acid 1.000mg PP1M 150mg (once) 13/09/22 1.000mg No EP003ESL Paranoid schizophrenia No 17/04/2019 Yes Olanzapine 10mg BZD PP3M 525mg 10/08/22 1.000mg Sedation (low) EP004ACG Paranoid schizophrenia No - Yes Quetiapine 50mg PP3M 525mg 16/09/22 1.000mg No EP005DCP Paranoid schizophrenia No 16/01/2004 Yes Olanzapine 20mg BZD PP3M 525mg 11/10/22 1.000mg No EP006ATT Persistent delusional disorder Yes - No PP3M 525mg 19/09/22 1.000mg No EP007AH Paranoid schizophrenia No 2017 No PP3M 525mg 03/08/22 1.000mg No EP008IAR Persistent delusional disorder Yes - Yes BZD Paliperidone oral 9mg and later PP3M 350mg (twice) 18/10/22 1.000mg No Fig. 1: Sociodemographic characteristics and Fig. 2: Clinical characteristics.
ConclusionsNone of the patients required hospitalization at the time of the study, although this work team considers that it is early to make conclusions in this regard. No serious or minor adverse effects were reported in any of the cases during the time of the investigation, apart from one case of mild sedation.
The clinical characteristics of most patients were psychopathological stability and good adherence to previous treatment. Although this study shows that the drug was also used in patients who did not meet these characteristics, specially one case of poor social support. The data collected show that the profile of the patient in whom the drug has been prescribed can be varied and broad.
Disclosure of InterestNone Declared